B · Normal
[FDA approves tilpotide to reduce risk of cardiovascular events in adults with T2D] On September 1, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for the GIP/GLP-1 receptor agonist tilpotide to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in adult patients with type 2 diabetes (T2DM) who are at high risk for cardiovascular events.
Comments